Community grieves over Hill's retirement

Emporia Gazette - 15 hours ago
Johnsen, who was diagnosed with...

Microsoft makes grants to extend Internet in remote areas

Roanoke Times - 13 hours ago
But unlike expensive and ambitious...

Community Notes

Cape Cod Times (subscription) - 3 days ago
For more information, contact Lynn...

'Right to Try' Bill in Senate for Terminally Ill Patients

Medscape - 1 week ago
Both bills would prevent the FDA...

A hearing brought to tears over Right to Try legislation

The Hill (blog) - 1 week ago
Bellina, a 32-year-old former Navy...

Incident Action Plans for Technical Rescue (press release) (registration) (blog) - 1 week ago
Consider the distance, terrain and...

Chester County biopharm firm targeting Lou Gehrig's disease with new licensing deal

Philadelphia Business Journal - 3 weeks ago
Filled with "must read"...

Regulators Tell Frontotemporal Dementia Community: We Play on Your Team

Alzforum - 4 weeks ago
A: We are willing to consider...

Lawmakers Discuss Challenges, Opportunities For FL Healthcare

WFSU - 4 weeks ago
“Where Florida needs to invest...

RFID News Roundup

RFID Journal - 4 weeks ago
Checkpoint Systems has announced...

News via Google. See more news matching 'als expanded access'


Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.